Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 12, 2006, Pages 1311-1319

  Lin, Lan ^a   Verslype, Chris ^a   Van Pelt, Jos F ^a   Van Ranst, Marc ^b   Fevery, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acute hepatitis; Chronic hepatitis; Coinfection; Fulminant hepatitis; Hepatitis virus; Hepatocellular carcinoma; Mutation; Viral interaction

Indexed keywords

ALPHA INTERFERON; CYTOKINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; RIBAVIRIN; VIRUS RNA;

CANCER RISK; DELTA AGENT HEPATITIS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMORAL IMMUNITY; LIVER CELL CARCINOMA; LIVER NECROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; VIRUS CARCINOGENESIS; VIRUS INTERFERENCE; VIRUS REACTIVATION;

ANIMALS; CYTOKINES; GENES, VIRAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; MUTATION;

EID: 33750966159     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000243881.09820.09     Document Type: Review

References (108)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-675.
2. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995; 90:201-205.
3. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepatitis 1995; 2:39-45.
4. Hasle G, Hoel T, Jensenius M. Mortality of hepatitis A in adults with hepatitis C antibodies. Lancet 1998; 351:1888.
5. Leino T, Leinikki P, Hyypia T, Ristola M, Suni J, Sutinen J, et al. Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland. Scand J Infect Dis 1997; 29:213-216.
6. Battegay M, Naef M, Bucher HC. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C [letter]. N Engl J Med 1998; 338:286-290.
7. Syed NA, Hearing SD, Shaw IS, Probert CS, Brooklyn TN, Caul EO, et al. Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur J Gastroenterol Hepatol 2003; 15:901-906.
8. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-290.
9. Brotman B, Prince AM, Huima T, Richardson L, van den Ende MC, Pfeifer U. Interference between non-A, non-B and hepatitis B virus infection in chimpanzees. J Med Virol 1983; 11:191-205.
10. Coppola N, Marrocco C, Di Caprio D, Coviello G, Scolastico C, Filippini P, et al. Acute hepatitis B and C virus co-infection: a virological and clinical study of 3 cases. Clin Infect Dis 2003; 36:528-532.
11. Chu CM, Liaw YF. Simultaneous acute hepatitis B virus and hepatitis C virus infection leading to fulminant hepatitis and subsequent chronic hepatitis C. Clin Infect Dis 1995; 20:703-705.
12. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992; 165:831-834.
13. Liaw YF, Tsai SL, Chang JJ, Sheen IS, Chien RN, Lin DY, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994; 106:1048-1053.
14. Chu CM, Yeh CT, Sheen IS, Liaw YF. Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV. Gut 2002; 51:95-99.
15. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, et al. Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection. Dig Dis Sci 2004; 49:281-288.
16. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36:1285-1291.
17. Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 1999; 19:348-353.
18. Gruener NH, Jung MC, Ulsenheimer A, Gerlach TJ, Diepolder HM, Schirren CA, et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol 2002; 37:866-869.
19. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95:2978-2980.
20. Sergi C, Arnold JC, Rau W, Otto HF, Hofmann WJ. Single nucleotide insertion in the 5′-untranslated region of hepatitis C virus with clearance of the viral RNA in a liver transplant recipient during acute hepatitis B virus superinfection. Liver 2002; 22:79-82.
21. Dai CY, Yu ML, Chuang WL, Lin ZY, Chen SC, Hsieh MY, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001; 16:636-640.
22. Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003; 39:1036-1041.
23. Koike K, Yasuda K, Yotsuyanagi H, Moriya K, Hino K, Kurokawa K, et al. Dominant replication of either virus in dual infection with hepatitis viruses B and C. J Med Virol 1995; 45:236-239.
24. Wang YM, Ng WC, Lo SK. Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the National University Hospital of Singapore. J Gastroenterol 1999; 34:481-485.
25. Chu CM, Sheen IS, Liaw YF. Low-level hepatitis C viremia and humoral immune response to NS4 in chronic hepatitis B virus-hepatitis C virus coinfection. Scand J Gastroenterol 2004; 39:778-782.
26. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28:27-33.
27. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32:1106-1110.
28. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-26.
29. Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, et al. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 2002; 97:1518-1523.
30. Greub G, Fei PC. Isolated antibody to hepatitis B core is associated with hepatitis C virus co-infection. Eur J Clin Microbiol Infect Dis 2000; 6:629.
31. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23:14-20.
32. Kao JH, Chen PJ, Lai MY, Chen DS. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002; 68:216-220.
33. Mathurin P, Thibault V, Kadidja K, Ganne-Carrie N, Moussalli J, El Younsi M, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepatitis 2000; 7:15-22.
34. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105:1529-1533.
35. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34:404-410.
36. Liaw YF, Tsai SL, Sheen IS, Chao M, Yeh CT, Hsieh SY, et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93:354-359.
37. Sheen IS, Liaw YF, Lin DY, Chu CM. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994; 170:358-361.
38. Qiu W, Hou J, Lou K. Low frequency of precore stop mutation in patients with dual infection of hepatitis B and C viruses. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1998; 12:133-135.
39. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in haemodialysis patients with chronic HCV infection. J Hepatol 2003; 38:506-510.
40. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993; 67:5823-5832.
41. Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278:591-607.
42. Dumoulin FL, von dem Bussche A, Li J, Khamzina L,Wands JR, Sauerbruch T, et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology 2003; 305:260-266.
43. Chen KL, Chen CM, Shih CM, Huang HL, Lee YH, Chang C, et al. Hepatitis B viral polymerase fusion proteins are biologically active and can interact with the hepatitis C virus core protein in vivo. J Biomed Sci 2001; 8:492-503.
44. Schüttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37:855-862.
45. Shih CM, Chen CM, Chen SY, Lee YH. Modulation of the transsuppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995; 69:1160-1171.
46. Uchida T, Kaneita Y, Gotoh K, Kanagawa H, Kouyama H, Kawanishi T, et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol 1997; 52:399-405.
47. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus co-infection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58:201-207.
48. Murakami S. Hepatitis B virus X protein: structure, function and biology. Intervirology 1999; 42:81-99.
49. Twu JS, Robinson WS. Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc Natl Acad Sci USA 1989; 86:2046-2050.
50. Marriott SJ, Lee TH, Slagle BL, Butel JS. Activation of the HTLV-I long terminal repeat by the hepatitis B virus X protein. Virology 1996; 224:206-213.
51. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001; 61:7803-7810.
52. Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MB, et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996; 93:4589-4594.
53. Cavanaugh VJ, Guidotti LG, Chisari FV. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol 1998; 72:2630-2637.
54. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91.
55. Davis GL, Hoofnagle JH, Waggoner JG. Acute type A hepatitis during chronic hepatitis B virus infection: association of depressed hepatitis B virus replication with appearance of endogenous alpha interferon. J Med Virol 1984; 14:141-147.
56. van Nunen AB, Pontesilli O, Uytdehaag F, Osterhaus AD, de Man RA. Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production. Liver 2001; 21:45-49.
57. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436:939-945.
58. Boni C, Amadei B, Urbani S, Fisicaro P, Zerbini A, Mori C, et al. Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. Hepatology 2004; 40:289-299.
59. Ohkawa K, Hayashi N, Yuki N, Masuzawa M, Kato M, Yamamoto K, et al. Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 1995; 46:258-264.
60. Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996; 206:149-173.
61. Gow P, Hathaway M, Gunson B, Heward J, Mutimer D. Association of fulminant non-A non-B hepatitis with homozygosity for HLA A1-B8-DR3. J Gastroenterol Hepatol 2005; 20:555-561.
62. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40:341-352.
63. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxford) 1996; 44:635-642.
64. Sezaki H, Arase Y, Tsubota A, Suzuki Y, Kobayashi M, Saitoh S, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003; 38:493-500.
65. Rocca P, Codes L, Chevallier M, Trepo C, Zoulim F. Autoimmunization induced by interferon alpha therapy in chronic hepatitis C. Gastroenterol Clin Biol 2004; 28:1173-1176.
66. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997; 16:445-451.
67. Ilan Y, Ashur Y, Tur-Kaspa R, Shouval D. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci 1994; 30:259-263.
68. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997; 44:1404-1406.
69. Guptan RC, Thakur V, Malhotra V, Sarin SK. Clinical implications of viral activity in dual infection with hepatitis B and C in chronic liver disease. J Assoc Physicians India 2002; 50:651-655.
70. Stransky J, Malina L, Cieslarova B, Stritesky J, Putova I, Horak J. Overt and hidden coinfection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda. Acta Virol 2000; 44:23-28.
71. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40:4068-4071.
72. Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004; 29:160-166.
73. Fujiwara K, Tanaka Y, Orito E, Ohno T, Kato T, Sugauchi F, et al. Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease. J Gastroenterol Hepatol 2004; 19:1343-1347.
74. Silva C, Goncales NS, Pereira JS, Escanhoela CA, Pavan MH, Goncales FL Jr. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients. Braz J Infect Dis 2004; 8:431-419.
75. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132-2137.
76. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354.
77. Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Gelatti U. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81:695-699.
78. Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004; 112:1075-1080.
79. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92:607-612.
80. Urashima T, Saigo K, Kobayashi S, Imaseki H, Matsubara H, Koide Y, et al. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. J Hepatol 1997; 26:771-778.
81. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31:552-558.
82. Chiba T, Matsuzaki Y, Abei M, Shoda J, Tanaka N, Osuga T, et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996; 91:1195-1203.
83. Dutta U, Byth K, Kench J, Khan MH, Coverdale SA,Weltman M, et al. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. Aust N Z J Med 1999; 29:300-307.
84. Imazeki F, Yokosuka O, Fukai K, Hiraide A, Saisho H. Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2003; 48:1786-1792.
85. Fujioka S, Shimomura H, Iwasaki Y, Fujio K, Nakagawa H, Onishi Y, et al. Hepatitis B virus gene in liver tissue promotes hepatocellular carcinoma development in chronic hepatitis C patients. Dig Dis Sci 2003; 48:1920-1924.
86. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999; 86:793-798.
87. Tamori A, Nishiguchi S, Kubo S, Enomoto M, Koh N, Takeda T, et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol 2003; 69:475-481.
88. Matsuzaki Y, Chiba T, Hadama T, Asaoka H, Doy M, Shoda J, et al. HBV genome integration and genetic instability in HBsAg-negative and anti-HCV-positive hepatocellular carcinoma in Japan. Cancer Lett 1997; 119:53-61.
89. Tamori A, Nishiguchi S, Kubo S, Koh N, Moriyama Y, Fujimoto S, et al. Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Hepatology 1999; 29:1429-1434.
90. Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, et al. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998; 37:260-269.
91. Locarnini S. A virological perspective on the need for vaccination. J Viral Hepatitis 2000; 7 (Suppl 1):5-6.
92. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16:95-97.
93. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27:881-886.
94. Wiedmann M, Liebert UG, Oesen U, Porst H,Wiese M, Schroeder S, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31:230-234.
95. Chlabicz S, Lapinski TW, Grzeszczuk A, Prokopowicz D. Four-year follow up of hepatitis C patients vaccinated against hepatitis B virus. World J Gastroenterol 2005; 11:1798-1801.
96. Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. Eur J Gastroenterol Hepatol 2002; 14:485-489.
97. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97:3171-3176.
98. Sarobe P, Lasarte JJ, Casares N, Lopez-Diaz de Cerio A, Baixeras E, Labarga P, et al. Abnormal priming of CD4+ T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76:5062-5070.
99. Brady MT, MacDonald AJ, Rowan AG, Mills KH. Hepatitis C virus nonstructural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol 2003; 33:3448-3457.
100. Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z Gastroenterol 2003; 41:983-990.
101. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97:435-439.
102. Zignego AL, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51:313-318.
103. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Stanzione M, Filippini P, et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol 2001; 65:681-687.
104. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DC. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37:568-576.
105. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005; 20:727-732.
106. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999; 14:893-898.
107. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
108. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129.